vs

Side-by-side financial comparison of Ginkgo Bioworks Holdings, Inc. (DNA) and SmartRent, Inc. (SMRT). Click either name above to swap in a different company.

SmartRent, Inc. is the larger business by last-quarter revenue ($36.5M vs $33.4M, roughly 1.1× Ginkgo Bioworks Holdings, Inc.). On growth, SmartRent, Inc. posted the faster year-over-year revenue change (3.1% vs -23.8%). SmartRent, Inc. produced more free cash flow last quarter ($7.7M vs $-47.7M). Over the past eight quarters, Ginkgo Bioworks Holdings, Inc.'s revenue compounded faster (-6.2% CAGR vs -15.0%).

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It...

Budget Rent a Car System, Inc. is an American car rental company that was founded in 1958 in Los Angeles, California by Morris Mirkin. Budget is a subsidiary of the Avis Budget Group, with its operations headquartered in Parsippany, New Jersey.

DNA vs SMRT — Head-to-Head

Bigger by revenue
SMRT
SMRT
1.1× larger
SMRT
$36.5M
$33.4M
DNA
Growing faster (revenue YoY)
SMRT
SMRT
+27.0% gap
SMRT
3.1%
-23.8%
DNA
More free cash flow
SMRT
SMRT
$55.3M more FCF
SMRT
$7.7M
$-47.7M
DNA
Faster 2-yr revenue CAGR
DNA
DNA
Annualised
DNA
-6.2%
-15.0%
SMRT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DNA
DNA
SMRT
SMRT
Revenue
$33.4M
$36.5M
Net Profit
$-3.2M
Gross Margin
38.6%
Operating Margin
-211.9%
-10.9%
Net Margin
-8.9%
Revenue YoY
-23.8%
3.1%
Net Profit YoY
71.6%
EPS (diluted)
$-1.41
$-0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DNA
DNA
SMRT
SMRT
Q4 25
$33.4M
$36.5M
Q3 25
$38.8M
$36.2M
Q2 25
$49.6M
$38.3M
Q1 25
$48.3M
$41.3M
Q4 24
$43.8M
$35.4M
Q3 24
$89.0M
$40.5M
Q2 24
$56.2M
$48.5M
Q1 24
$37.9M
$50.5M
Net Profit
DNA
DNA
SMRT
SMRT
Q4 25
$-3.2M
Q3 25
$-80.8M
$-6.3M
Q2 25
$-60.3M
$-10.9M
Q1 25
$-91.0M
$-40.2M
Q4 24
$-11.4M
Q3 24
$-56.4M
$-9.9M
Q2 24
$-217.2M
$-4.6M
Q1 24
$-165.9M
$-7.7M
Gross Margin
DNA
DNA
SMRT
SMRT
Q4 25
38.6%
Q3 25
26.4%
Q2 25
33.1%
Q1 25
32.8%
Q4 24
28.7%
Q3 24
33.2%
Q2 24
35.7%
Q1 24
38.5%
Operating Margin
DNA
DNA
SMRT
SMRT
Q4 25
-211.9%
-10.9%
Q3 25
-231.8%
-19.4%
Q2 25
-132.1%
-30.5%
Q1 25
-184.1%
-99.9%
Q4 24
-236.3%
-36.6%
Q3 24
-62.0%
-29.0%
Q2 24
-396.7%
-14.3%
Q1 24
-469.1%
-20.1%
Net Margin
DNA
DNA
SMRT
SMRT
Q4 25
-8.9%
Q3 25
-207.9%
-17.3%
Q2 25
-121.6%
-28.3%
Q1 25
-188.2%
-97.2%
Q4 24
-32.3%
Q3 24
-63.3%
-24.5%
Q2 24
-386.4%
-9.5%
Q1 24
-437.3%
-15.2%
EPS (diluted)
DNA
DNA
SMRT
SMRT
Q4 25
$-1.41
$-0.02
Q3 25
$-1.45
$-0.03
Q2 25
$-1.10
$-0.06
Q1 25
$-1.68
$-0.21
Q4 24
$-1.91
$-0.06
Q3 24
$-1.08
$-0.05
Q2 24
$-4.23
$-0.02
Q1 24
$-3.32
$-0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DNA
DNA
SMRT
SMRT
Cash + ST InvestmentsLiquidity on hand
$422.6M
$104.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$508.6M
$232.1M
Total Assets
$1.1B
$320.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DNA
DNA
SMRT
SMRT
Q4 25
$422.6M
$104.5M
Q3 25
$495.5M
$100.0M
Q2 25
$559.4M
$105.0M
Q1 25
$325.3M
$125.6M
Q4 24
$561.6M
$142.5M
Q3 24
$616.2M
$163.4M
Q2 24
$730.4M
$187.4M
Q1 24
$840.4M
$204.7M
Stockholders' Equity
DNA
DNA
SMRT
SMRT
Q4 25
$508.6M
$232.1M
Q3 25
$559.8M
$234.4M
Q2 25
$613.0M
$238.8M
Q1 25
$647.4M
$250.7M
Q4 24
$716.1M
$289.4M
Q3 24
$797.9M
$305.1M
Q2 24
$833.1M
$329.4M
Q1 24
$987.3M
$333.1M
Total Assets
DNA
DNA
SMRT
SMRT
Q4 25
$1.1B
$320.9M
Q3 25
$1.2B
$335.8M
Q2 25
$1.2B
$354.0M
Q1 25
$1.3B
$366.1M
Q4 24
$1.4B
$420.2M
Q3 24
$1.5B
$448.6M
Q2 24
$1.6B
$475.3M
Q1 24
$1.6B
$485.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DNA
DNA
SMRT
SMRT
Operating Cash FlowLast quarter
$-47.7M
$7.7M
Free Cash FlowOCF − Capex
$-47.7M
$7.7M
FCF MarginFCF / Revenue
-142.8%
21.0%
Capex IntensityCapex / Revenue
0.0%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-25.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DNA
DNA
SMRT
SMRT
Q4 25
$-47.7M
$7.7M
Q3 25
$-31.6M
$-2.1M
Q2 25
$-40.3M
$-14.9M
Q1 25
$-51.5M
$-12.2M
Q4 24
$-42.4M
$-12.0M
Q3 24
$-103.5M
$-3.7M
Q2 24
$-84.4M
$-13.9M
Q1 24
$-89.3M
$-3.3M
Free Cash Flow
DNA
DNA
SMRT
SMRT
Q4 25
$-47.7M
$7.7M
Q3 25
$-2.2M
Q2 25
$-40.3M
$-16.2M
Q1 25
$-59.1M
$-14.3M
Q4 24
$-56.1M
$-13.3M
Q3 24
$-118.6M
$-3.9M
Q2 24
$-111.4M
$-14.1M
Q1 24
$-96.0M
$-3.4M
FCF Margin
DNA
DNA
SMRT
SMRT
Q4 25
-142.8%
21.0%
Q3 25
-6.1%
Q2 25
-81.2%
-42.3%
Q1 25
-122.4%
-34.7%
Q4 24
-128.0%
-37.5%
Q3 24
-133.2%
-9.7%
Q2 24
-198.2%
-29.1%
Q1 24
-252.9%
-6.7%
Capex Intensity
DNA
DNA
SMRT
SMRT
Q4 25
0.0%
0.0%
Q3 25
0.0%
0.2%
Q2 25
0.1%
3.3%
Q1 25
15.8%
5.3%
Q4 24
31.3%
3.5%
Q3 24
16.9%
0.6%
Q2 24
48.1%
0.5%
Q1 24
17.7%
0.1%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DNA
DNA

Cell Engineering Segment$26.0M78%
Other$7.4M22%

SMRT
SMRT

Hosted Services$18.1M50%
Hardware Service$12.5M34%
Smart Operations Solutions$2.6M7%
Access Control$2.0M5%
Other Smart Communities Solutions$1.3M3%

Related Comparisons